Tsc2 — Tuberous Sclerosis Complex 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tuberous Sclerosis Complex 2 (TSC2) encodes the protein tuberin, a crucial tumor suppressor protein that forms a functional complex with TSC1 (hamartin). This complex is a master regulator of the mTOR (mechanistic target of rapamycin) signaling pathway, controlling cell growth, proliferation, and metabolism. Mutations in TSC2 cause tuberous sclerosis complex, a genetic disorder characterized by benign tumors throughout the body and significant neurological manifestations including epilepsy, intellectual disability, and autism. [1]
| Property | Value | [2]
|----------|-------| [3]
| Gene Symbol | TSC2 | [4]
| Full Name | Tuberous Sclerosis Complex 2 | [5]
| Chromosomal Location | 16p13.3 | [6]
| NCBI Gene ID | 7249 |
| Ensembl ID | ENSG00000103197 |
| OMIM ID | 191221 |
| UniProt ID | P49815 |
| Protein Name | Tuberin |
| Molecular Weight | ~200 kDa |
Tuberin is a 1,807 amino acid protein containing several functional domains including a GAP (GTPase-activating protein) domain that specifically targets the small GTPase Rheb (Ras homolog enriched in brain)[1]. The TSC1-TSC2 heterodimer localizes primarily to the cytoplasm and intracellular membranes, where it senses cellular energy status and growth factor signals.
The TSC1-TSC2 complex serves as the primary negative regulator of mTORC1 (mechanistic target of rapamycin complex 1), a central kinase complex that controls protein synthesis, cell growth, and metabolism:
Beyond mTOR regulation, TSC2 participates in:
Approximately 70-80% of TSC cases are caused by mutations in TSC2, making it the more common genetic cause of the disorder[3]. TSC2 mutations typically cause more severe disease compared to TSC1 mutations:
TSC2 is part of a broader category of "mTORopathies" - neurological disorders characterized by mTOR pathway dysregulation[4]. These include:
mTOR inhibitors (everolimus, sirolimus) are first-line treatments for TSC-related complications:
Tuberin is ubiquitously expressed with high levels in:
In neurons, TSC2 is localized to synapses and regulates dendritic spine morphology and synaptic plasticity.
The study of Tsc2 — Tuberous Sclerosis Complex 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Links verified: 2026-03-16
Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit and stimulate mTOR. 2002. ↩︎
Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. 2016. ↩︎
Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the EXIST-1 trial. 2013. ↩︎
Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. 2008. ↩︎
McMahon J, McDowell S, Egelhoff J, et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND). 2012. ↩︎
Inoki K, Corradetti MN, Guan KL. TSC2: a core component of the nutrient/energy-responsive complex that integrates growth factor and nutrient signals. 2005. ↩︎